{"id":3611,"date":"2024-01-22T13:40:01","date_gmt":"2024-01-22T13:40:01","guid":{"rendered":"http:\/\/drhimanshuyadav.com\/bms-opdivo-regimen-shows-promise-in-colorectal-cancer-clinical-trials\/"},"modified":"2024-01-22T13:40:01","modified_gmt":"2024-01-22T13:40:01","slug":"bms-opdivo-regimen-shows-promise-in-colorectal-cancer-clinical-trials","status":"publish","type":"post","link":"https:\/\/drhimanshuyadav.com\/blog\/bms-opdivo-regimen-shows-promise-in-colorectal-cancer-clinical-trials\/","title":{"rendered":"BMS’ Opdivo regimen shows promise in colorectal cancer clinical trials"},"content":{"rendered":"
\n

<\/p>\n

<\/p>\n

\n
\n
BMS’ Opdivo plus Yervoy significantly improved progression-free survival in patients with MSI-H\/dMMR metastatic colorectal cancer. Credit: Bristol-Myers Squibb Company.<\/figcaption><\/figure>\n<\/p><\/div>\n

bristol myers squib<\/a> (BMS) is a Phase III CheckMate-8HW clinical trial combining Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment option for microsatellite-high instability (MSI-H) or mismatch repair deficiency (dMMR). reported promising data. Metastatic colorectal cancer (mCRC).<\/p>\n

This open-label, randomized Phase 3 study was designed to evaluate Opdivo in combination with Yervoy against the investigator’s choice of chemotherapy.<\/p>\n

Approximately 830 patients were enrolled and randomly assigned to receive Opdivo monotherapy, Opdivo plus Yervoy, or chemotherapy.<\/p>\n

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, while chemotherapy regimens include mFOLFOX-6 or FOLFIRI with or without bevacizumab or cetuximab.<\/p>\n

The study’s dual primary endpoints focused on progression-free survival (PFS) of Opdivo combination therapy versus chemotherapy in the first-line setting.<\/p>\n

The other primary endpoint was PFS in subjects receiving Opdivo alone across all treatments.<\/p>\n

\n

Access the most comprehensive company profiles on the market with GlobalData. Save research time. Increase competitiveness.<\/p>\n